Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series-Reference-Cited by-同舟云学术

Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series

Published:2024-03-08 Issue: Volume: Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Masuda Takashi,Funakoshi Taro,Horimatsu Takahiro,Yamamoto Shinya,Matsubara Takeshi,Masui Sho,Nakagawa Shunsaku,Ikemi Yasuaki,Yanagita Motoko,Muto Manabu,Terada Tomohiro,Yonezawa Atsushi

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00280-024-04659-3.pdf

Reference27 articles.

1. Gill KL, Machavaram KK, Rose RH, Chetty M (2016) Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet 55:789–805. https://doi.org/10.1007/s40262-015-0361-4

2. Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 14(2):296–302. https://doi.org/10.1208/s12248-012-9340-y

3. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70:1208–1215. https://doi.org/10.1136/ard.2011.153023

4. Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D (2016) Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet 55:1381–1394. https://doi.org/10.1007/s40262-016-0406-3

5. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D (2005) Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 52:2693–2696. https://doi.org/10.1002/art.21266